Investigation Launched: BioAge Labs Investors May Pursue Class Action Lawsuit

LOS ANGELES
,

Feb. 12, 2025

/PRNewswire/ —
Glancy Prongay & Murray LLP announces that investors with losses have the opportunity to lead a securities
fraud class action lawsuit against BioAge Labs, Inc. (“BioAge” or the “Company”)
BIOA.

IF YOU SUFFERED A LOSS ON YOUR BIOAGE INVESTMENTS, CLICK HERE BEFORE MARCH 10, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT

What is the Lawsuit About?

The complaint claims that, since the Registration Statement related to the Company’s
September 2024 initial public offering, several important facts were not disclosed to investors. Specifically, the allegations include: (1) a risk of liver transaminitis in prior clinical Phase 1 trials and preclinical toxicity studies; (2) possible safety issues with the ongoing STRIDES clinical trial; (3) overstatements regarding the likelihood of completing the ongoing STRIDES study; (4) exaggeration about the potential outcomes of a second Phase 2 clinical trial using azelaprag and semaglutide to treat obesity in adults; and (5) that the positive claims made by the Company lacked truth and reasonable basis at all relevant times.

Contact Us To Participate or Learn More:

If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights with respect to these matters, please reach out.

Charles Linehan, Esq.,

Glancy Prongay & Murray LLP,

1925 Century Park East, Suite 2100,

Los Angeles California 90067

Email: [email protected]

Telephone: 310-201-9150 (Toll-Free: 888-773-9224) 

Visit our website at www.glancylaw.com.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you inquire by email, please include your mailing address, telephone number, and the number of shares purchased.

To join the class action, no action is necessary at this time; you can choose either to hire your own legal counsel or remain an absent member of the class action.

This press release may be seen as Attorney Advertising in some jurisdictions under applicable laws and ethical rules.

Contact Us:

Glancy Prongay & Murray LLP,

1925 Century Park East, Suite 2100,

Los Angeles, CA 90067


Charles Linehan

Email: [email protected]

Telephone: 310-201-9150

Toll-Free: 888-773-9224

Visit our website at: www.glancylaw.com.

View original content to download multimedia:
https://www.prnewswire.com/news-releases/bioage-labs-inc-bioa-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302374448.html

SOURCE
Glancy Prongay & Murray LLP